Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
70 hedge funds and large institutions have $742M invested in Turning Point Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 70 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$111M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$106M |
| 3 |
O
OrbiMed
New York
|
+$91.6M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$65.3M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
+$47.8M |
Top Sellers
TPTX Hedge Fund Activity: Q2 2019 in Review
70 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q2 2019, worth a combined $742M.
Buyers outnumbered sellers: 70 funds opened new TPTX positions and 0 closed out — a net gain of 70 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $111M.
- 70 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $742M of Turning Point Therapeutics, Inc. Common Stock stock for Q2 2019.
- 70 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +70 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q2 2019 was Cormorant Asset Management, an estimated $111M added.
Based on aggregated 13F filings for Q2 2019.